Risk factors
Medicinova (MNOV) risk factors
Item 1A of every Medicinova Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks4 new4 dropped5 reworded
Net loss increased to $12.0 million in 2025 with an accumulated deficit reaching $438.7 million. Added specific risks regarding inflation, tariffs, and FDA review impacts.
Filed Mar 10, 2026 - FY2024 10-K risk factors56 risks
MMedicinovas risk profile centers on ongoing operating losses, lack of commercialized products, and reliance on drug candidates MN-166 and MN-001. Clinical trial failures, regulatory hurdles, and third-party manufacturing dependencies threaten its long-term viability. International operations and complex licensing agreements add further operational risks.
Filed Feb 19, 2025